OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of chemotherapy resistance in ovarian cancer
Mylena Ortiz, Emma Wabel, Kerry Mitchell, et al.
Cancer Drug Resistance (2022)
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Unveiling the mechanisms and challenges of cancer drug resistance
Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 102

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
Giovanni Tossetta
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12893-12893
Open Access | Times Cited: 52

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae‐Weon Kim, Richard T. Penson, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 50-62
Open Access | Times Cited: 30

Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
Yulun Wu, Chaoran Jia, Wei Liu, et al.
Journal of Advanced Research (2024) Vol. 65, pp. 89-104
Open Access | Times Cited: 11

Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance
Celine Kapper, Peter Oppelt, Barbara Arbeithuber, et al.
Life Sciences (2024) Vol. 349, pp. 122720-122720
Open Access | Times Cited: 10

Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers
Nooshafarin Shirani, N. Abdi, Matin Chehelgerdi, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access | Times Cited: 1

Long noncoding RNATUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta
Ryosuke Sonobe, Peng Yang, Miho Suzuki, et al.
Cancer Science (2024) Vol. 115, Iss. 6, pp. 1910-1923
Open Access | Times Cited: 7

Iron promotes ovarian cancer malignancy and advances platinum resistance by enhancing DNA repair via FTH1/FTL/POLQ/RAD51 axis
Qingyu Zhang, Caiyun Chen, Xinxin Zou, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 7

Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Effat Alemzadeh, Leila Allahqoli, Afrooz Mazidimoradi, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 831-847
Open Access | Times Cited: 6

Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer
Karen Geoffroy, Victor Mullins‐Dansereau, Kim Leclerc-Desaulniers, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200826-200826
Open Access | Times Cited: 5

Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7
Xin Pan, Xiu Shi, Hong Zhang, et al.
Gene (2024) Vol. 927, pp. 148738-148738
Closed Access | Times Cited: 5

Recent Advances in the Biomedical Applications of Functionalized Nanogels
Kannan Badri Narayanan, Rakesh Bhaskar, Sung Soo Han
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2832-2832
Open Access | Times Cited: 22

The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models
Vanja Tadić, Zhang We, Anamaria Brozović
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1879, Iss. 1, pp. 189052-189052
Closed Access | Times Cited: 13

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options
Mariana Nunes, Carla Bartosch, Miguel Henriques Abreu, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 786-786
Open Access | Times Cited: 4

Claudin-4 Modulates Autophagy via SLC1A5/LAT1 as a Mechanism to Regulate Micronuclei
Fabian R. Villagómez, Julie Lang, Fredrick J. Rosario, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 7, pp. 1625-1642
Open Access | Times Cited: 4

Molecular biology as a driver in therapeutic choices for ovarian cancer
Martina Arcieri, Claudia Andreetta, Veronica Tius, et al.
International Journal of Gynecological Cancer (2024), pp. ijgc-005700
Closed Access | Times Cited: 4

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
Edgar Yebrán Villegas-Vázquez, Francisco Pável Marín-Carrasco, Octavio D. Reyes‐Hernández, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access

Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity
Jae Hyun Kim, Ja‐Young Han, Jae-Hee Kwon, et al.
Investigational New Drugs (2025)
Closed Access

A Novel SHAP-GAN Network for Interpretable Ovarian Cancer Diagnosis
Jinhai Cai, Zne-Jung Lee, Zhouchen Lin, et al.
Mathematics (2025) Vol. 13, Iss. 5, pp. 882-882
Open Access

Page 1 - Next Page

Scroll to top